Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Catalytic Reductive Amination. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel six-step synthesis route for complex azepine intermediates offering high purity, scalable manufacturing, and significant cost reduction for pharmaceutical applications.
Discover the patented bimetallic catalytic route for 5-[(phenylamino)methyl]-2-furanmethanol. Enhance supply chain reliability and reduce manufacturing costs with this green technology.
Patent CN101712623B details a cost-effective Pd/C catalyzed route for Methoxyphenamine Hydrochloride, offering >99% purity and superior supply chain reliability.
Patent CN101712623A details a high-yield Pd/C catalyzed route for Methoxyphenamine Hydrochloride, offering significant cost reduction and supply chain reliability for API manufacturers.
Patent CN111548275A details a robust 5-step synthesis for AP20187 intermediates. Discover cost-effective manufacturing and scalable supply chain solutions for high-purity pharmaceutical building blocks.
Patent CN118291412A reveals a novel Leucine Dehydrogenase for efficient L-Phosphinothricin and L-Phenylglycine synthesis, offering significant cost reduction and supply chain reliability.
Patent CN108003141A reveals a safer alfuzosin route. Achieve cost reduction in pharmaceutical intermediates manufacturing with stable yields and scalable processes.
Patent CN108178761A reveals a mild PtO2 catalytic route for Sitagliptin. This method offers significant cost reduction and supply chain reliability for API manufacturing.
Patent CN111689933B details a green one-pot reductive amination using biomass-derived HMF and nitrobenzene, offering significant cost reduction and supply chain reliability for fine chemical manufacturing.
Patent CN101270058B details a high-yield hydrogenation route for 3-(1-dimethylaminoethyl)phenol, offering superior purity and cost efficiency for Alzheimer's drug intermediates.
Patent CN104277018B enables high-purity 2 5-dimethylaminofuran production. Offers cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN112209837A reveals a novel reductive amination route for Butenafine HCl, offering superior purity and cost reduction in API manufacturing compared to traditional chloromethylation methods.
Patent CN109824539B details a novel 6-step Tigecycline synthesis from Demethyl Aureomycin, offering high purity, cost reduction, and scalable manufacturing for pharmaceutical intermediates.